Specialty Pharmacy

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

Growth in midlife mortality includes conditions such as heart disease, liver cancer, pulmonary disease, obesity, and neurologic disorders.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, talks about why pharmacists should pursue continuing education to benefit their patients.

A second unexpected impurity was shown in 3 lots of Torrent Pharmaceuticals’ recalled drug products during an ongoing FDA investigation.

Pamrevlumab is advancing towards phase 3 clinical development for idiopathic pulmonary fibrosis early next year.

Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with hairy cell leukemia.

The FDA has accepted for review Regeneron Pharmaceuticals’ supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat diabetic retinopathy.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Tocilizumab’s newest formulation offers an additional administration option for children diagnosed systemic juvenile idiopathic arthritis, a rare and debilitating disease.

More than 65% of patients with Kaposi’s sarcoma in a small cohort had partial or complete remission when treated with immune checkpoint inhibitors.

Top news of the day from across the health care landscape.

B cells activate T cells in the blood to cause inflammation and brain lesions in patients with multiple sclerosis.

One in 5 test results showed potentially dangerous concurrent use of opioids and benzodiazepines in 2017.

With Hurricane Florence about to strike, pharmacies must take extra steps to maintain services for patients in need of lifesaving medications.

Early-life obesity increases the risk of several different types of cancer developing later in life.

Top news of the day from across the health care landscape.

In its multiple-ascending dose trial, ARO-HBV demonstrated reductions in circulating hepatitis B virus surface antigen.

Study identifies a potential association between azathioprine and the mutational signature found in cases of cutaneous squamous cell carcinoma.

The FDA is taking new steps to better ensure the quality of compounded drugs, while also preserving patient access to these medications.

Study shows a novel treatment approach that could prevent gene changes associated with the disease.

Top news of the day from across the health care landscape.

Treatment with tezepelumab reduced annual asthma exacerbation rates in patients with severe asthma without an eosinophilic phenotype.

Treatment with ibudilast reduced the progression of brain atrophy in patients with progressive multiple sclerosis compared with a placebo.

Officials with the FDA have approved a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film for the maintenance treatment of opioid dependence.

Top news of the day from across the health care landscape.

Achilles Alon, PharmD, RPh, Director of Specialty Pharmacy, Co-owner of ACE-Rx Specialty Pharmacy, discusses the potential for specialty pharmacies to become the norm.

The new formulation is the only immune globulin available in the United States that is approved for post-exposure protection against hepatitis A and measles.